Combination of a glycomimetic antagonist tp e-selectin and CXCR4, GMI-1359, with an anti-PD-L1 antibody attenuates regulatory T cell infiltration and accelerates time to complete response in the murine CT26 tumor model
![](https://content.labcorp.com/sites/default/files/biopharma_knowledge_library/posters/SITC-2016-Poster.pdf.png)
Individuals & Patients
Health Systems & Organizations
Find Locations
For hours, walk-ins and appointments.